NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
Clinical Trials
37 trialsNCT00213486 2026-04-06
Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial
University Hospital, Rouen
Phase 2 Completed
NCT00033657 2023-06-28
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00318903 2023-05-25
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT00911820 2022-11-08
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00381706 2021-09-29
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01928290 2020-08-25
FOLFIRINOX
Washington University School of Medicine
Phase 2 Completed
NCT00003748 2020-08-03
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00020761 2020-08-03
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01498289 2019-11-07
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT01608464 2018-08-10
Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer
King Faisal Specialist Hospital & Research Center
Phase 2 Terminated
NCT00316862 2018-05-08
Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00183872 2018-02-19
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
University of Southern California
Phase 2 Completed
NCT00256269 2018-01-26
Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma
University of California, Irvine
Phase 2 Terminated
NCT00848783 2018-01-08
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
NYU Langone Health
Phase 2 Terminated
NCT00201747 2017-12-06
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00137852 2017-09-20
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00394433 2017-08-01
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00400114 2017-05-08
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00836277 2016-11-15
Phase II Study of Irinotecan and Panitumumab
University of Pittsburgh
Phase 2 Completed
NCT00003137 2016-07-14
Irinotecan in Treating Patients With Advanced Cancer of the Stomach
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00004235 2016-07-14
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00354679 2016-05-16
Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00737438 2016-02-03
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00590031 2016-01-25
Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00397904 2015-11-25
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00109850 2015-11-18
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
SWOG Cancer Research Network
Phase 2 Terminated
NCT00183807 2014-05-22
A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
University of Southern California
Phase 2 Terminated
NCT00005607 2013-12-19
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003055 2013-06-21
Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00030862 2013-06-05
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00012363 2012-06-14
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
SWOG Cancer Research Network
Phase 2 Completed
NCT00520091 2012-05-18
Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00813072 2012-03-02
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
PharmaEngine
Phase 2 Completed
NCT00215995 2012-01-13
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00165464 2009-04-28
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00075738 2008-07-24
Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown